Semaglutide Medications Show Promise in Reducing Cardiovascular Events and Kidney Disease Progression
Semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, has demonstrated significant benefits beyond weight loss and type 2 diabetes management. Large-scale trials, such as the SELECT study involving over 17,000 adults, revealed that semaglutide lowered the risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, by 20% in individuals with established heart disease and overweight or obesity. This benefit was observed regardless of the amount of weight lost, with waist size reduction showing a stronger correlation to heart protection than total weight loss. Additionally, the FLOW trial indicated that semaglutide reduced the risk of major kidney disease events by 24% and cardiovascular death by 18% in adults with type 2 diabetes and chronic kidney disease. These findings have led to FDA approvals for Wegovy to reduce cardiovascular risk in specific populations and for Ozempic to slow kidney disease progression and lower cardiovascular death risk in type 2 diabete...